Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27042239 | 0.84 | CETP (0.47) | CETPCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11759783 | 0.79 | PTPN1 (0.46) | PTPN1CETPGGPS1 | |
| SCHEMBL30722883 | 0.76 | PGK1 (0.37) | S1PR1S1PR3GGPS1 | |
| SCHEMBL11764166 | 0.74 | GGPS1 (0.47) | PTPN1CETPS1PR1S1PR3GGPS1 | |
| SCHEMBL10331192 | 0.71 | CYP1A2 (0.52) | FNTAFNTB | |
| SCHEMBL11761689 | 0.71 | PTPN1 (0.60) | PTPN1CETP | |
| SCHEMBL11760531 | 0.71 | PTPN1 (0.49) | PTPN1 | |
| SCHEMBL14533598 | 0.69 | HDAC3 (0.40) | CYP3A4 | |
| SCHEMBL5550099 | 0.68 | CETP (0.47) | CETPCYP3A4 | |
| SCHEMBL11406548 | 0.68 | PTPN1 (0.46) | PTPN1CETPGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | ACHE, BCHE, MUSK | PTPN1 2182/4885CETP 75/4885S1PR1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.